Hooman Rashidi, MD

Dr. Rashidi combines his passion for patient care and education with his unique training in bioinformatics and machine learning (ML) to create innovative new tools and resources that improve clinical practice, research and education.

His experience in ML dates back to his graduate years at UCSD which subsequently allowed him to serve as the principal author and editor of several popular bioinformatics textbooks. This background has also enabled him to develop various novel AI-ML platforms. Before joining the Cleveland Clinic as the Director of PLMI’s Center for Artificial Intelligence and Data Science & Vice Chair of Technology Innovation & Computational Pathology, he served as the Director of AI for University of California Davis Medical Center and Professor & Vice chair of informatics and Computational pathology (until Dec 2021), leading a large number of AI / ML studies with numerous collaborators from various prominent institutions. These studies have led to numerous products and filed patents along with a large number of manuscripts in which he serves as corresponding author. One of his most exciting & well-established inventions is the proprietary Automated Machine Learning (Auto-ML) software MILO (Machine Intelligence Learning Optimizer). MILO”s suite of applications includes its powerful Auto-ML platform and 6 unique complimentary preprocessing and statistics Data Science Apps which have been licensed to several industry and academic institutions & serving as a powerful suite of data science tools for a large number of clinical, quality and educational projects.

Most recently, he has also developed a new powerful novel automated synthetic data generator known as STNG (Synthetic Tabular Neural Generator) that will be available soon to all (through Cleveland Clinic) to help revolutionize our research & quality study realm by addressing various data access and data optimization needs.

In addition to the above, he is also a well-known educator with numerous teaching awards who has created some of the AppStore’s most popular hematology Apps. He is also the co-founder and senior editor of HematologyOutlines, a very popular online hematology atlas that is used internationally and endorsed by the American Society of Clinical Pathology.

Dr. Rashidi’s efforts in the AI-ML & digital space are widely recognized, as evidenced by his continuous invited talks (at numerous prestigious conferences / institutions), his various editorial & reviewer roles, the multitude of key invited review articles & his continued national committee roles within this space.

Education & Professional Highlights

Appointed
2022

Education & Fellowships

Fellowship - UCLA David Geffen School of Medicine & UCLA Health System
Hematopathology
Los Angeles, CA USA
2009

Residency - Yale New Haven Medical Center & School of Medicine
Anatomic and Clinical Pathology
New Haven, CT USA
2008

Internship - Beth Israel Deaconess Medical Center and Harvard Medical School
Internal Medicine
Boston, MA USA
2004

Medical Education - University of Texas Health Science Center at San Antonio - School of Medicine
San Antonio, TX USA
2003

Graduate School - University of California San Diego
Biology
La Jolla, CA USA
1998

Undergraduate - University of California San Diego
Biochemistry
La Jolla, CA USA
1997

Additional Training

Professional Highlights

Certifications

Pathology - Hematopathology
Pathology - Anatomic & Clinical Pathology

Awards & Honors

Innovations & Patents

Memberships

Research & Publications

See publications for Hooman Rashidi, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/12/2023, Dr. Rashidi has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Equity Dr. Rashidi owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

MILO-ML, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Primary Location

Cleveland Clinic Main Campus

Additional Locations

Insurance

Is Cleveland Clinic Part of Your Insurance?

About Hooman Rashidi, MD